Other real-world studies also showed SGLT2 inhibitors were associated with a lower risk of all-cause death compared with other diabetes drugs (HR 0.51; 95% CI 0.37, 0.70; p < 0.001) [55]. The gene discussed is SLC5A2; the disease is diabetes mellitus.